All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

Amgen Inc (NASDAQ:AMGN) reported better-than-expected fourth-quarter results on Tuesday, but its shares fell 1.5% in premarket trading Wednesday as the company's profit outlook for 2025 fell short of ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...